Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.
ACE inhibitor–induced angioedema
Bradykinin
C1-inhibitor
Difficult airway
Quincke disease
Journal
Emergency medicine clinics of North America
ISSN: 1558-0539
Titre abrégé: Emerg Med Clin North Am
Pays: United States
ID NLM: 8219565
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
entrez:
16
11
2021
pubmed:
17
11
2021
medline:
23
11
2021
Statut:
ppublish
Résumé
Angioedema is a well-recognized and potentially lethal complication of angiotensin-converting enzyme inhibitor (ACEi) therapy. In ACEi-induced angioedema, bradykinin accumulates due to a decrease in its metabolism by ACE, the enzyme that is primarily responsible for this function. The action of bradykinin at bradykinin type 2 receptors leads to increased vascular permeability and the accumulation of fluid in the subcutaneous and submucosal space. Patients with ACEi-induced angioedema are at risk for airway compromise because of the tendency for the face, lips, tongue, and airway structures to be affected. The emergency physician should focus on airway evaluation and management when treating patients with ACEi-induced angioedema.
Identifiants
pubmed: 34782093
pii: S0733-8627(21)00100-0
doi: 10.1016/j.emc.2021.09.004
pii:
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-98Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.